deltatrials
Terminated PHASE2 NCT02030405

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

A Phase 2 Study of Single-Agent MLN9708 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia With Mutated Nucleophosmin-1

Sponsor: National Cancer Institute (NCI)

Conditions Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) Adult Acute Myeloblastic Leukemia Without Maturation (M1) Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Acute Myelomonocytic Leukemia (M4) Adult Erythroleukemia (M6a) Adult Pure Erythroid Leukemia (M6b) Recurrent Adult Acute Myeloid Leukemia
Interventions Ixazomib
Updated 8 times since 2017 Last updated: Apr 1, 2019 Started: Mar 31, 2014 Primary completion: Nov 30, 2015 Completion: Nov 30, 2015

Listed as NCT02030405, this PHASE2 trial focuses on Adult Acute Megakaryoblastic Leukemia (M7) and Adult Acute Minimally Differentiated Myeloid Leukemia (M0) and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. May 2019 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Jun 2018 — May 2019 [monthly]

    Terminated PHASE2

▶ Show 3 earlier versions

  1. May 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Feb 2017 — May 2017 [monthly]

    Terminated PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Steven E. Coutre
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Stanford, United States